Market Overview

Vetr Crowd Downgrades Tetraphase

  • Shares of Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) have lost nearly 75 percent of value year-to-date.
  • The Vetr crowd downgraded Tetraphase to a rating of four stars out of a possible five.
  • Despite a downgrade, the Vetr crowd still sees upside in Tetraphase's stock as 66 percent of the crowd's ratings are bullish.

Tetraphase Pharmaceuticals, a clinical-stage biopharmaceutical company that develops antibiotics for serious and life-threatening multidrug-resistant infections, saw its stock plunge by around 80 percent in early September after the top-line results from a phase 3 trial failed to meet its primary endpoint.

Related Link: Tetraphase's Stock Just Lost 80%, You Should Flush It...Right?

Tetraphase's stock hit a 52-week low of $7.20 following the phase 3 trial and have since rebounded to the $10 level. The Vetr crowd on Wednesday downgraded the company to a four star out of five rating from a prior 4.5-star rating. Meanwhile, 66 percent of the crowd's ratings are bullish.

Matthew Waterman, a member of the Vetr crowd, pointed out that since Tetraphase develops antibiotics to combat infections, the company likely controls a product "that is pretty marketable to the right consumer." He added that the stock may fit the profile of a Speculative Buy, especially when factoring in the company's market cap is "only about a third larger than their asset value."

Waterman placed a $12 price target on Tetraphase. However, his price target along with the crowd-sourced price target of $11.66 is less ambitious than some of Wall Street's pros. On November 19, analysts at SunTrust Robinson Humphrey upgraded Tetraphase to Buy from Neutral with a price target raised to $21 from a previous $12.

Latest Ratings for TTPH

Oct 2019UpgradesHoldBuy
Sep 2019DowngradesBuyNeutral
Mar 2019DowngradesBuyHold

View More Analyst Ratings for TTPH
View the Latest Analyst Ratings

Posted-In: biopharmaceuticals Tetraphase Pharmaceuticals Vetr Vetr CrowdAnalyst Color Crowdsourcing Analyst Ratings General


Related Articles (TTPH)

View Comments and Join the Discussion!

Latest Ratings

WMTRaymond JamesMaintains130.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

How E-Commerce Companies Will Continue To Take Share Away From Wal-Mart

Alibaba Finds Resistance Again At The $85 Level